梅奥联盟肥大细胞增多症预后系统:临床与混合临床-分子模型
该研究基于梅奥诊所1968至2015年580例系统性肥大细胞增多症患者,评估临床与临床-遗传学整合风险模型的可行性。多变量分析识别出年龄>60岁、晚期SM、血小板减少、贫血及ALP升高为独立生存风险因素,ASXL1、RUNX1、NRAS突变亦与较差生存独立相关。研究据此开发了两种互补的风险模型,强调突变的独立预后贡献。
要点
- 年龄>60岁、晚期SM、血小板<150×10⁹/L、贫血、ALP升高为独立生存风险因素。
- ASXL1、RUNX1、NRAS突变与较差生存独立相关。
- 研究开发了临床与混合临床-分子两种互补风险模型。
核心结论
- 本研究提出了两种互补的系统性肥大细胞增多症风险模型,并强调突变具有独立预后贡献。
研究设计与样本
- 研究纳入1968至2015年在梅奥诊所就诊的580例系统性肥大细胞增多症患者,中位年龄55岁(范围18-88岁),诊断符合世界卫生组织(WHO)标准,部分患者有核型和下一代测序数据。
主要发现
- 形态学亚类为惰性/冒烟型291例(50%),晚期289例(50%),其中伴相关血液肿瘤199例、侵袭性系统性肥大细胞增多症85例、肥大细胞白血病5例。
- 临床变量多变量分析显示,年龄>60岁、晚期SM、血小板<150×10⁹/L、贫血低于性别校正正常值、碱性磷酸酶(ALP)升高为独立生存风险因素,风险比(HR)及95%置信区间(95%CI)分别为2.5(1.9-3.4)、2.7(1.8-4.0)、2.5(1.9-3.4)、2.2(1.6-3.1)、2.1(1.5-3.0)。
- ASXL1(HR 4.5,95%CI 2.6-7.6)、RUNX1(HR 4.3,95%CI 1.3-10.8)、NRAS(HR 5.0,95%CI 1.5-13.2)突变与较差生存独立相关。
- 联合临床、细胞遗传学和分子风险因素分析证实,不良突变(HR 2.6,95%CI 1.6-4.4)、晚期SM(HR 4.0,95%CI 1.8-10.0)、血小板减少(HR 2.8,95%CI 1.7-4.5)、ALP升高(HR 2.1,95%CI 1.2-4.0)、年龄>60岁(HR 2.2,95%CI 1.3-3.6)具有独立预后贡献。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic mastocytosis (SM) is a clinically heterogeneous disease with prognosis chiefly assigned based on World Health Organization (WHO) morphologic subclassification. We assessed the feasibility of developing contemporary risk models for SM based on clinical and integrated clinical-genetics information. Diagnosis of SM was per WHO criteria, and karyotype and next-generation sequencing data were available in a subset of the total 580 patients (median age, 55 years; range, 18-88 years) seen at the Mayo Clinic between 1968 and 2015. Morphologic subcategories were indolent/smoldering in 291 (50%) and "advanced" in 289 (50%): SM with an associated hematological neoplasm in 199, aggressive SM in 85, and mast cell leukemia in 5. Multivariable analysis of clinical variables identified age >60 years, advanced SM, thrombocytopenia <150 × 109/L, anemia below sex-adjusted normal, and increased alkaline phosphatase (ALP) as independent risk factors for survival; respective hazard ratios (HRs) 95% confidence intervals (95% CIs) were 2.5 (1.9-3.4), 2.7 (1.8-4.0), 2.5 (1.9-3.4), 2.2 (1.6-3.1), and 2.1 (1.5-3.0). In addition, ASXL1 (HR, 4.5; 95% CI, 2.6-7.6), RUNX1 (HR, 4.3; 95% CI, 1.3-10.8), and NRAS (HR, 5.0, 95% CI, 1.5-13.2) mutations were independently associated with inferior survival. Combined clinical, cytogenetic, and molecular risk factor analysis confirmed the independent prognostic contribution of adverse mutations (2.6, 1.6-4.4), advanced SM (4.0, 1.8-10.0), thrombocytopenia (2.8, 1.7-4.5), increased ALP (2.1, 1.2-4.0), and age >60 years (2.2, 1.3-3.6). These data were subsequently used to develop clinical and hybrid clinical-molecular risk models. The current study advances 2 complementary risk models for SM and highlights the independent prognostic contribution of mutations.
引用
- Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018. PMID: 30413432. doi:10.1182/bloodadvances.2018026245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。